GlassScriptPhysician profile
Kevin Hamilton
NPI 1770071177
$2,833.45
in general payments reported to CMS, 2019-2025
25 companies · $104 in 2025
The $104 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $392 · 2022: $1,354 · 2023: $983 · 2025: $104.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,087.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,087.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $348.23 | 2021-2023 | Prolia, Evenity, Repatha |
| Lilly USA, LLC | $329.49 | 2022-2023 | Mounjaro, Jardiance, Trulicity |
| Novo Nordisk INC | $303.88 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $214.89 | 2021-2025 | Farxiga |
| Glaxosmithkline, LLC. | $210.76 | 2021-2023 | Trelegy Ellipta, Shingrix, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $173.68 | 2021-2023 | Spiriva Respimat, Tradjenta, Synjardy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $150.61 | 2022-2023 | Xifaxan, Trulance |
| Dexcom, INC. | $146.94 | 2022-2023 | Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Idorsia Pharmaceuticals US INC | $102.38 | 2022-2023 | Quviviq |
| Novartis Pharmaceuticals Corporation | $100.39 | 2022-2023 | |
| Abbvie INC. | $96.57 | 2021-2023 | |
| Sanofi-Aventis U.S. LLC | $85.41 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $74.05 | 2022 | |
| Janssen Pharmaceuticals, INC | $73.61 | 2022-2023 | Spravato |
| Pfizer INC. | $73.43 | 2022-2023 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $65.86 | 2022-2023 | Injectafer |
| Esperion Therapeutics, INC. | $57.00 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $41.41 | 2021 | |
| Exact Sciences Corporation | $35.79 | 2023 | Cologuard Collection Kit |
| Biohaven Pharmaceuticals, INC. | $34.16 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $29.46 | 2021-2022 | |
| Eisai INC. | $29.22 | 2021 | |
| Merck Sharp & Dohme LLC | $25.73 | 2021-2022 | |
| Abbott Laboratories | $16.65 | 2023 | Proclaim |
| Bayer Healthcare Pharmaceuticals INC. | $13.85 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Hamilton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.